1-5 of 5
Robert Mashal, MD
Close
Sort by
Journal Articles

Pharmacokinetics and Pharmacodynamics after Subcutaneous Dosing of the iNKT Cell Depleting Antibody NKTT120

Robert Schaub, PhD, Abraham Thariath, PhD, Felix Scheuplein, PhD, Robert Mashal, MD
Journal: Blood
Blood (2015) 126 (23): 4575.
https://doi.org/10.1182/blood.V126.23.4575.4575
Published: 2015
Journal Articles

Adult Patients with Stable Sickle Cell Disease Prior to Treatment with the iNKT Cell Depleting Antibody NKTT120 Have Consistent and Elevated Numbers of Activated (CD69 + ) iNKT Cells Relative to Healthy Adult Volunteers

Rosemary Mazanet, MD PhD, Robert Schaub, PhD, Felix Scheuplein, PhD, Cheryl A. Eaton, BA, Robert Mashal, MD, Joshua J. Field, MD MS
Journal: Blood
Blood (2014) 124 (21): 4097.
https://doi.org/10.1182/blood.V124.21.4097.4097
Published: 2014
Journal Articles

Antibody Mediated Depletion of iNKT Cells Protects Against Hypoxia-Induced Pulmonary Injury in a Murine Model of Sickle Cell Disease

Hong Pei, PhD, Robert Schaub, PhD, Felix Scheuplein, PhD, Robert Mashal, MD, Joel Linden, PhD
Journal: Blood
Blood (2014) 124 (21): 2697.
https://doi.org/10.1182/blood.V124.21.2697.2697
Published: 2014
Journal Articles

Mouse Invariant TCR Specific Monoclonal Antibody NKT14: A Novel Tool To Manipulate Invariant NKT Cell Function In Vivo

Felix Scheuplein, Ph.D., Abraham Thariath, Ph.D., Robert Mashal, MD, Robert Schaub, Ph.D.
Journal: Blood
Blood (2013) 122 (21): 3478.
https://doi.org/10.1182/blood.V122.21.3478.3478
Published: 2013
Journal Articles

A Phase I Single Ascending Dose Study Of NKTT120 In Stable Adult Sickle Cell Patients

Joshua J. Field, MD, MS, Kenneth I. Ataga, MD, Elaine Majerus, MD, PhD, Cheryl A. Eaton, BA, Robert Mashal, MD, David G. Nathan, MD
Journal: Blood
Blood (2013) 122 (21): 977.
https://doi.org/10.1182/blood.V122.21.977.977
Published: 2013